Investors Overview

Esperion is a pharmaceutical company passionately committed to developing and commercializing non-statin, once-daily, oral therapies to lower elevated low-density lipoprotein (LDL) cholesterol for patients with hypercholesterolemia not adequately treated with current lipid-modifying therapies. Bempedoic acid is being developed as a once-daily, oral inhibitor of ATP Citrate Lyase (ACL), and is designed to bring a targeted mechanism of action to address patients’ unmet medical needs.

Esperion has been a publicly traded company since 2013 and is listed on the NASDAQ Global Select Market under the symbol ESPR.

**Esperion Therapeutics** () on
Last Price	Change	open	Day High	52-Week High
Last Price	Volume	Previous Close	Day Low	52-Week Low

Press Releases

Date	Title and Summary
Toggle Summary Nov 22, 2019	Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) ANN ARBOR, Mich., Nov. 22, 2019 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that, on November 20, 2019, the Compensation Committee of Esperion’s Board of Directors granted 61,705 restricted stock units (RSUs) to fifty-four new colleagues under Esperion’s 2017 Inducement Equity
Toggle Summary Nov 17, 2019	Esperion Announces Pooled Analyses from Phase 3 LDL-C Lowering Clinical Development Program of Bempedoic Acid Presented at the American Heart Association 2019 Scientific Sessions ANN ARBOR, Mich., Nov. 17, 2019 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that pooled analyses from four Phase 3 clinical studies of bempedoic acid were presented at the American Heart Association (AHA) Scientific Sessions in Philadelphia.
Toggle Summary Nov 12, 2019	Esperion Announces Publication in the Journal of the American Medical Association of Bempedoic Acid Phase 3 Study 2 Results – Study 2 Demonstrated that Bempedoic Acid Significantly Lowered LDL-Cholesterol and Reduced hsCRP – – Over 52- Weeks, Overall Adverse Events in the Bempedoic Acid Treatment Arm were Comparable to Placebo – – Bempedoic Acid is being developed as an Oral, Once-daily ATP Citrate Lyase (ACL)
Toggle Summary Nov 7, 2019	Esperion to Participate in Upcoming Investor Conferences ANN ARBOR, Mich., Nov. 07, 2019 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR), today announced that the company will participate in fireside chats at the following conferences: Credit Suisse 28 th Annual Healthcare Conference in Phoenix on Tuesday, November 12, 2019 3:50 PM EST Stifel Healthcare
Toggle Summary Nov 6, 2019	Esperion Provides Bempedoic Acid Franchise Development Program Updates; Reports Third Quarter Financial Results ANN ARBOR, Mich., Nov. 06, 2019 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) today provided bempedoic acid franchise development program updates and financial results for the third quarter ended September 30, 2019. “The Esperion Lipid Management Team continues to lay a strong and durable foundation